Addition of αGal HyperAcute™ technology to recombinant avian influenza vaccines induces strong low-dose antibody responses.

by Wenlan Alex Chen, Jinjin Zhang, Katie M Hall, Carol B Martin, Serguei Kisselev, Emily J Dasen, Nicholas N Vahanian, Charles J Link, Brian K Martin
Published 2017-01-01

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma

by Ramses Sadek, Olivier Rixe, David Munn, Christopher M Smith, Yousef Zakharia, Joseph Drabick, Kenneth F Grossmann, Robert R McWilliams, Montaser F Shaheen, Ravindra Kolhe, Rafal Pacholczyk, Lucinda L Tennant, Eugene P Kennedy, Charles J Link Jr, Nicholas N Vahanian, Jiayi Yu, Steven S Shen, Erik L Brincks, Gabriela R Rossi
Published 2021-06-01

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

by Asha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, Robin Dobbins, Lisa Marshall, Nicholas N. Vahanian, W. Jay Ramsey, Eugene Kennedy, Mario R. Mautino, Charles J. Link, Ray S. Lin, Stephanie Royer-Joo, Xiaorong Liang, Laurent Salphati, Kari M. Morrissey, Sami Mahrus, Bruce McCall, Andrea Pirzkall, David H. Munn, John E. Janik, Samir N. Khleif
Published 2018-06-01